These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1237 related articles for article (PubMed ID: 22108192)

  • 1. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
    Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
    Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
    Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
    Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLK1 Is transcriptionally activated by NF-κB during cell detachment and enhances anoikis resistance through inhibiting β-catenin degradation in esophageal squamous cell carcinoma.
    Lin DC; Zhang Y; Pan QJ; Yang H; Shi ZZ; Xie ZH; Wang BS; Hao JJ; Zhang TT; Xu X; Zhan QM; Wang MR
    Clin Cancer Res; 2011 Jul; 17(13):4285-95. PubMed ID: 21610149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma.
    Yan S; Zhou C; Zhang W; Zhang G; Zhao X; Yang S; Wang Y; Lu N; Zhu H; Xu N
    Cancer Lett; 2008 Nov; 271(1):85-97. PubMed ID: 18602747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
    Li Y; Fu L; Li JB; Qin Y; Zeng TT; Zhou J; Zeng ZL; Chen J; Cao TT; Ban X; Qian C; Cai Z; Xie D; Huang P; Guan XY
    Gastroenterology; 2014 Jun; 146(7):1701-13.e9. PubMed ID: 24561231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD.
    Jang MS; Lee SJ; Kim CJ; Lee CW; Kim E
    Oncogene; 2011 Jan; 30(4):471-81. PubMed ID: 20890306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
    Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
    Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.
    Zhang X; Zhang J; Wang L; Wei H; Tian Z
    BMC Cancer; 2007 Aug; 7():149. PubMed ID: 17683579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y; Yang Z; Li Q; Song F
    Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T; Tabuchi Y; Hayashi A; Kondo T
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1.
    Wang Z; Zhu S; Shen M; Liu J; Wang M; Li C; Wang Y; Deng A; Mei Q
    Carcinogenesis; 2013 Mar; 34(3):678-88. PubMed ID: 23172665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
    Feng B; Wang R; Chen LB
    Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.